vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $13.8M, roughly 1.5× CB Financial Services, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs -65.2%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-39.7M). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
CBFV vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $20.6M |
| Net Profit | — | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | 38.1% | -106.0% |
| Net Margin | — | -84.4% |
| Revenue YoY | 19.9% | -65.2% |
| Net Profit YoY | — | -173.8% |
| EPS (diluted) | $0.90 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $13.5M | — | ||
| Q1 25 | $12.1M | $20.6M | ||
| Q4 24 | $13.2M | $37.4M | ||
| Q3 24 | $12.7M | $19.6M | ||
| Q2 24 | $12.2M | $94.7M | ||
| Q1 24 | $13.5M | $59.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $1.9M | $-17.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $3.2M | $-14.0M | ||
| Q2 24 | $2.6M | $55.0M | ||
| Q1 24 | $4.2M | $23.5M |
| Q4 25 | 38.1% | — | ||
| Q3 25 | -289.8% | — | ||
| Q2 25 | 35.0% | — | ||
| Q1 25 | 19.3% | -106.0% | ||
| Q4 24 | 23.1% | -15.7% | ||
| Q3 24 | 31.2% | -110.7% | ||
| Q2 24 | 26.4% | 56.4% | ||
| Q1 24 | 37.9% | 35.7% |
| Q4 25 | — | — | ||
| Q3 25 | -235.2% | — | ||
| Q2 25 | 29.3% | — | ||
| Q1 25 | 15.8% | -84.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | 25.3% | -71.7% | ||
| Q2 24 | 21.8% | 58.1% | ||
| Q1 24 | 31.1% | 39.7% |
| Q4 25 | $0.90 | — | ||
| Q3 25 | $-1.07 | — | ||
| Q2 25 | $0.74 | — | ||
| Q1 25 | $0.35 | $-0.42 | ||
| Q4 24 | $0.45 | $-0.20 | ||
| Q3 24 | $0.60 | $-0.35 | ||
| Q2 24 | $0.51 | $1.55 | ||
| Q1 24 | $0.82 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $157.5M | $417.3M |
| Total Assets | $1.5B | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | — | ||
| Q3 25 | $55.9M | — | ||
| Q2 25 | $64.5M | — | ||
| Q1 25 | $61.3M | $67.8M | ||
| Q4 24 | $49.6M | $101.2M | ||
| Q3 24 | $147.3M | $78.0M | ||
| Q2 24 | $142.6M | $185.3M | ||
| Q1 24 | $73.7M | $68.4M |
| Q4 25 | $157.5M | — | ||
| Q3 25 | $152.5M | — | ||
| Q2 25 | $148.4M | — | ||
| Q1 25 | $148.3M | $417.3M | ||
| Q4 24 | $147.4M | $428.7M | ||
| Q3 24 | $149.1M | $422.4M | ||
| Q2 24 | $142.9M | $429.9M | ||
| Q1 24 | $141.6M | $269.4M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | $486.5M | ||
| Q4 24 | $1.5B | $526.3M | ||
| Q3 24 | $1.6B | $554.6M | ||
| Q2 24 | $1.6B | $582.0M | ||
| Q1 24 | $1.5B | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-38.5M |
| Free Cash FlowOCF − Capex | $17.2M | $-39.7M |
| FCF MarginFCF / Revenue | 124.1% | -192.9% |
| Capex IntensityCapex / Revenue | 4.7% | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $4.1M | — | ||
| Q1 25 | $4.0M | $-38.5M | ||
| Q4 24 | $6.8M | $-31.6M | ||
| Q3 24 | $3.1M | $-24.3M | ||
| Q2 24 | $-1.2M | $39.8M | ||
| Q1 24 | $3.3M | $-25.5M |
| Q4 25 | $17.2M | — | ||
| Q3 25 | $4.5M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $3.9M | $-39.7M | ||
| Q4 24 | $3.4M | $-32.2M | ||
| Q3 24 | $2.2M | $-24.9M | ||
| Q2 24 | $-2.4M | $38.8M | ||
| Q1 24 | $2.3M | $-26.4M |
| Q4 25 | 124.1% | — | ||
| Q3 25 | 186.5% | — | ||
| Q2 25 | 28.8% | — | ||
| Q1 25 | 32.5% | -192.9% | ||
| Q4 24 | 26.0% | -86.2% | ||
| Q3 24 | 17.4% | -127.3% | ||
| Q2 24 | -19.6% | 41.0% | ||
| Q1 24 | 17.0% | -44.6% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 0.8% | 5.6% | ||
| Q4 24 | 25.1% | 1.7% | ||
| Q3 24 | 6.7% | 3.3% | ||
| Q2 24 | 10.0% | 1.1% | ||
| Q1 24 | 7.2% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | 0.72× | ||
| Q1 24 | 0.78× | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
